ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Jul 2022
Last Updated on 01 Jul 2022

A- A+

Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended listing emicizumab on the Medication Assistance Fund (MAF) in line with its registered indication as prophylaxis for patients with haemophilia A with or without factor VIII inhibitors to prevent or reduce bleeding episodes, due to unfavourable cost-effectiveness compared with subsidised alternatives at the price proposed by the manufacturer.

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended listing emicizumab on the Medication Assistance Fund (MAF) in line with its registered indication as prophylaxis for patients with haemophilia A with or without factor VIII inhibitors to prevent or reduce bleeding episodes, due to unfavourable cost-effectiveness compared with subsidised alternatives at the price proposed by the manufacturer.

Emicizumab prophylaxis for patients with haemophilia A (1 Jul 22) Emicizumab prophylaxis for patients with haemophilia A PES (1 Jul 22)